The Union Health Ministry has proposed an amendment to the Drugs Rules, 1945 to close a regulatory gap in advertising prescription medicines. The proposal was publicised on 9 October and stems from Gazette Notification G.S.R. 861(E) dated 28 September.
Existing rules restrict advertising of Schedule H, H1 and X drugs by manufacturers without prior Central Government sanction. The proposed sub-rule under Rule 65 would extend the same restriction to licence holders who sell, stock, exhibit, offer for sale or distribute those medicines, including retail and wholesale drug licence holders.
The public-health rationale is to reduce unauthorised promotion of medicines that require professional supervision and thereby limit inappropriate self-medication. Advertising restrictions are one part of medicines regulation; prescription practices, pharmacy compliance, pharmacovigilance and public awareness also affect safe use.
For civil-services preparation, note the legal status: this is a draft amendment, not yet a final rule. Schedules H, H1 and X have different regulatory controls, but the proposed advertising restriction would apply across all three categories through the prior-sanction requirement.
